Experience in treating non-alcoholic fatty pancreas disease in a patient with metabolically complicated obesity: a clinical case

Obesity is currently widespread among the working population and is a pressing issue in modern medicine. It has been proven that complications of obesity are caused by the localization of fat accumulation. Ectopic deposition of adipose tissue is observed in the heart, liver, kidneys, muscles, and also in the pancreas. The role of obesity in the development of pancreatic pathologies is currently being actively studied. Pancreatic steatosis is the accumulation of intracellular fat in the organ tissues, which is accompanied by clinical and laboratory changes. In recent years, the term «non-alcoholic fatty pancreas disease» has been used to formulate a diagnosis. Currently, pancreatic steatosis remains a poorly understood problem of modern medicine. It is considered a diffuse process of development of adipose tissue in all part of the pancreas, occurring mainly against the background of metabolic syndrome and combined with sluggish inflammation of the organ under the influence of various damaging factors. Metabolic syndrome develops gradually and for a long time proceeds without obvious clinical symptoms. With a long course and progression, it can lead to the development of lipomatosis of internal organs, in particular, pancreatic steatosis. Disturbance of lipid metabolism is manifested by atherogenic dyslipidemia, in which the concentration of free fatty acids in the pancreatic parenchyma increases significantly, which in turn leads not only to a decrease in insulin activity, but also to dysfunction in cells, mainly to their apoptosis. This clinical analysis will examine the biochemical indicators of the functional state of the pancreas with steatotic degeneration, and also describe the experience of treating non-alcoholic fatty pancreas disease in a patient with metabolically complicated obesity.

1. Gubergrits N.B., Belyaeva N.V., Mozhina T.L. Parallels between non-alcoholic fatty liver disease and non-alcoholic fatty disease of the pancreas: in search of common ground or a look through the prism of the metabolic syndrome. Experimental and clinical gastroenterology. 2020:183(11):80-101. (in Russ.). DOI: 10.31146/1682-8658-ecg-183-11-80-101. EDN: FWXIVN.

2. Sevim B.C., Chela H., Ertugrul H., Malik L.S., Malik S., Basar O., Daglilar E., Samiullah S., et al. Non-Alcoholic Fatty Pancreas Disease: The Unsung Disease. Endocr Metab Immune Disord Drug Targets. 2023;23(4):485-493. DOI: 10.2174/1871530322666220929142905.

3. Bi Y., Wang J.L., Li M.L., Zhou J., Sun X.L. The association between pancreas steatosis and metabolic syndrome: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2019;35(5):e3142. DOI: 10.1002/dmrr.3142.

4. Tanaeva T.A., Ivanov L.A., Chernyshova T.E. Proceedings of the International Science Conference “SCIENCE. EDUCATION. PRACTICE” (January 29, 2025). Delhi. India. Part 1; 129-136. DOI 10.34660/INF.2025.66.88.060

5. Shpilevskaya Yu.R., Shtonda S.V. metabolic syndrome: modern aspects of diagnosis and treatment. Medical news. 2021;5(320):4-8 (in Russ.). EDN: HCJBZE.

6. Paul J., Shihaz A.V.H. Pancreatic steatosis: a new diagnosis and therapeutic challenge in gastroenterology. Arq Gastroenterol. 2020;57(2): 216-220. DOI: 10.1590/s0004-2803.202000000-27.

7. Tanaeva T.A., Ivanov L.A. Correlation between type 2 diabetes mellitus and pancreatic steatosis. Perm Medical Journal. 2023;40(2):5-10 (in Russ.). DOI: 10.17816/pmj4025-10. EDN: FUNXCK.